Oncology News | pharmaphorum

News

ESMO: Enhertu shows its worth in brain metastases

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

News

WCLC: Bayer, Boehringer face off on HER2 cancers

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to t

News

WCLC: Biomarker could guide Dato-DXd use in lung cancer

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dat

News

WCLC: Summit trumpets data with Keytruda challenger

MSD's PD-1 inhibitor Keytruda has ruled the immunotherapy of non-small cell lung cancer (NSCLC) for many years, but a bispecific antibody from Summit Therapeutics and partner Akeso looks li

News

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-st

News

ArsenalBio raises $325m for programmable CAR-T platform

Arsenal Biosciences has cleared an impressive $325 million from a third-round financing that will be used to fund clinical trials of its pipeline of CAR-T therapies, trying to break new gro

ESMO: Enhertu shows its worth in brain metastases

WCLC: Bayer, Boehringer face off on HER2 cancers

WCLC: Biomarker could guide Dato-DXd use in lung cancer

WCLC: Summit trumpets data with Keytruda challenger

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

ArsenalBio raises $325m for programmable CAR-T platform

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks